Corcept Therapeutics Management
Management criteria checks 2/4
Corcept Therapeutics' CEO is Joseph Belanoff, appointed in Jan 1999, has a tenure of 26.08 years. total yearly compensation is $9.34M, comprised of 11.6% salary and 88.4% bonuses, including company stock and options. directly owns 2.88% of the company’s shares, worth $202.25M. The average tenure of the management team and the board of directors is 4.3 years and 23.3 years respectively.
Key information
Joseph Belanoff
Chief executive officer
US$9.3m
Total compensation
| CEO salary percentage | 11.6% |
| CEO tenure | 26.1yrs |
| CEO ownership | 2.9% |
| Management average tenure | 4.3yrs |
| Board average tenure | 23.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$140m |
| Jun 30 2024 | n/a | n/a | US$125m |
| Mar 31 2024 | n/a | n/a | US$117m |
| Dec 31 2023 | US$9m | US$1m | US$105m |
| Sep 30 2023 | n/a | n/a | US$91m |
| Jun 30 2023 | n/a | n/a | US$94m |
| Mar 31 2023 | n/a | n/a | US$94m |
| Dec 31 2022 | US$7m | US$896k | US$101m |
| Sep 30 2022 | n/a | n/a | US$117m |
| Jun 30 2022 | n/a | n/a | US$113m |
| Mar 31 2022 | n/a | n/a | US$112m |
| Dec 31 2021 | US$11m | US$844k | US$113m |
| Sep 30 2021 | n/a | n/a | US$106m |
| Jun 30 2021 | n/a | n/a | US$98m |
| Mar 31 2021 | n/a | n/a | US$99m |
| Dec 31 2020 | US$6m | US$770k | US$106m |
| Sep 30 2020 | n/a | n/a | US$109m |
| Jun 30 2020 | n/a | n/a | US$114m |
| Mar 31 2020 | n/a | n/a | US$106m |
| Dec 31 2019 | US$5m | US$708k | US$94m |
| Sep 30 2019 | n/a | n/a | US$87m |
| Jun 30 2019 | n/a | n/a | US$78m |
| Mar 31 2019 | n/a | n/a | US$76m |
| Dec 31 2018 | US$6m | US$680k | US$75m |
Compensation vs Market: Joseph's total compensation ($USD9.34M) is above average for companies of similar size in the UK market ($USD3.28M).
Compensation vs Earnings: Joseph's compensation has increased by more than 20% in the past year.
CEO
Joseph Belanoff (67 yo)
26.1yrs
Tenure
US$9,337,734
Compensation
Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 26.1yrs | US$9.34m | 2.88% $ 202.3m | |
| CFO & Treasurer | 3.9yrs | US$3.72m | 0.012% $ 856.1k | |
| President of Endocrinology | 8.8yrs | US$3.91m | 0.10% $ 7.0m | |
| Chief Development Officer | 3.5yrs | US$3.86m | 0.0052% $ 367.4k | |
| Chief Business Officer & Secretary | 11.1yrs | US$3.96m | 0.041% $ 2.8m | |
| Chief Accounting & Technology Officer | 4.6yrs | no data | 0.0084% $ 586.2k | |
| Chief Scientific Officer | 4.6yrs | US$3.11m | 0.11% $ 7.9m | |
| Chief Human Resources & Communications Officer | 3.6yrs | no data | no data | |
| President of Emerging Markets | 1.3yrs | no data | no data | |
| President of Oncology | 1.1yrs | no data | no data |
4.3yrs
Average Tenure
53.5yo
Average Age
Experienced Management: 0I3Q's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 26.1yrs | US$9.34m | 2.88% $ 202.3m | |
| Independent Director | 26.1yrs | US$492.53k | 5.07% $ 355.4m | |
| Independent Director | 20.6yrs | US$509.03k | 1.25% $ 88.0m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman | 26.1yrs | US$1.26m | 2.25% $ 157.5m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.9yrs | US$511.53k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.4yrs | US$488.53k | 0% $ 0 |
23.3yrs
Average Tenure
68.5yo
Average Age
Experienced Board: 0I3Q's board of directors are seasoned and experienced ( 23.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/01 03:33 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Corcept Therapeutics Incorporated is covered by 22 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| David Buck | B. Riley Securities, Inc. |
| Edward Nash | Canaccord Genuity |